Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study ; volume:22 ; number:1 ; day:26 ; month:7 ; year:2023 ; pages:1-10 ; date:12.2023
Cardiovascular diabetology ; 22, Heft 1 (26.7.2023), 1-10, 12.2023
- Creator
-
Lim, Jaehyun
Choi, You-Jung
Kim, Bong Sung
Rhee, Tae-Min
Lee, Hyun-Jung
Han, Kyung-Do
Park, Jun-Bean
Na, Jin Oh
Kim, Yong-Jin
Lee, Heesun
Kim, Hyung-Kwan
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12933-023-01911-7
- URN
-
urn:nbn:de:101:1-2023102710380901847202
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lim, Jaehyun
- Choi, You-Jung
- Kim, Bong Sung
- Rhee, Tae-Min
- Lee, Hyun-Jung
- Han, Kyung-Do
- Park, Jun-Bean
- Na, Jin Oh
- Kim, Yong-Jin
- Lee, Heesun
- Kim, Hyung-Kwan
- SpringerLink (Online service)
Other Objects (12)
Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride
Effects of Empagliflozin and Dapagliflozin in alleviating cardiac fibrosis through SIRT6-mediated oxidative stress reduction
Dapagliflozin
Study comparing the efficacy and renal safety for patients with diabetes switching from dapagliflozin to empagliflozin
Empagliflozin and dapagliflozin decreased atrial monoamine oxidase expression and alleviated oxidative stress in overweight non-diabetic cardiac patients
Effects of the sodium-glucose cotransporter 2 inhibitors Canagliflozin, Dapagliflozin and Empagliflozin on endothelial barrier dysfunction : An in-vitro study
No cytotoxic and inflammatory effects of empagliflozin and dapagliflozin on primary renal proximal tubular epithelial cells under diabetic conditions in vitro
Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study
Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey
Flunarizine related movement disorders: a nationwide population-based study
Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study
Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride
Effects of Empagliflozin and Dapagliflozin in alleviating cardiac fibrosis through SIRT6-mediated oxidative stress reduction
Dapagliflozin
Study comparing the efficacy and renal safety for patients with diabetes switching from dapagliflozin to empagliflozin
Empagliflozin and dapagliflozin decreased atrial monoamine oxidase expression and alleviated oxidative stress in overweight non-diabetic cardiac patients
Effects of the sodium-glucose cotransporter 2 inhibitors Canagliflozin, Dapagliflozin and Empagliflozin on endothelial barrier dysfunction : An in-vitro study
No cytotoxic and inflammatory effects of empagliflozin and dapagliflozin on primary renal proximal tubular epithelial cells under diabetic conditions in vitro
Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study
Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey
Flunarizine related movement disorders: a nationwide population-based study
Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study
Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride
Effects of Empagliflozin and Dapagliflozin in alleviating cardiac fibrosis through SIRT6-mediated oxidative stress reduction
Dapagliflozin
Study comparing the efficacy and renal safety for patients with diabetes switching from dapagliflozin to empagliflozin
Empagliflozin and dapagliflozin decreased atrial monoamine oxidase expression and alleviated oxidative stress in overweight non-diabetic cardiac patients
Effects of the sodium-glucose cotransporter 2 inhibitors Canagliflozin, Dapagliflozin and Empagliflozin on endothelial barrier dysfunction : An in-vitro study
No cytotoxic and inflammatory effects of empagliflozin and dapagliflozin on primary renal proximal tubular epithelial cells under diabetic conditions in vitro
Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study
Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey
Flunarizine related movement disorders: a nationwide population-based study